Promethera® Therapeutics SA is a global innovator in the treatment of severe liver diseases, whose mission is to offer patients high technology treatments to increase the chances of survival and reduce the need for liver transplantation. Our main clinical program is derived from our patented HepaStem® cellular technology platform. HepaStem® is an advanced therapy medicinal product intended to bring an alternative to transplantation. HepaStem® is a drug manufactured from healthy human liver tissue and produced on a large scale under GMP (Good Manufacturing Practice) conditions. HepaStem® is administered by simple peripheral intravenous infusion and is transported through the bloodstream to the inflamed liver. Preclinical and clinical results suggest that HepaStem® may reduce inflammation and fibrosis through its ability to perform paracrine regenerative and immunomodulatory functions on CD4+ T cells and liver cells. These combined effects are expected to play a favorable role in the restoration of liver homeostasis. HepaStem® is currently being tested in ACLF (clinical Phase IIB). Additional liver diseases’ treatments are also under development pre-clinical stage.
Promethera® Therapeutics SA is a global innovator in the treatment of severe liver diseases, whose mission is to offer patients high technology treatments to increase the chances of survival and reduce the need for liver transplantation. Our main clinical program is derived from our patented HepaStem® cellular technology platform. HepaStem® is an advanced therapy medicinal product intended to bring an alternative to transplantation. HepaStem® is a drug manufactured from healthy human liver tissue and produced on a large scale under GMP (Good Manufacturing Practice) conditions. HepaStem® is administered by simple peripheral intravenous infusion and is transported through the bloodstream to the inflamed liver. Preclinical and clinical results suggest that HepaStem® may reduce inflammation and fibrosis through its ability to perform paracrine regenerative and immunomodulatory functions on CD4+ T cells and liver cells. These combined effects are expected to play a favorable role in the restoration of liver homeostasis. HepaStem® is currently being tested in ACLF (clinical Phase IIB). Additional liver diseases’ treatments are also under development pre-clinical stage.
Company Information
- Industry
- Biotechnology
- Company Type
- Privately Held
- Founded
- unknown
- Employee Range
- 51-200
- Revenue Range
- Not available
Location
- Address
- Rue Granbonpré 11 Wallonia Mont Saint Guibert
- City
- Charleroi
- Region
- Hainaut
- Postal Code
- 1435
- Country
- Belgium
